Table 2.
Summary of cited meta-analyses and randomized trials for head and neck cancer and rectal cancer.
| Reference | Year | Entity | Study type | Treatment arms | RT/CT schedule | P # | HT frequency | Outcome |
|---|---|---|---|---|---|---|---|---|
| Head and neck cancers | ||||||||
| Datta et al. (87) | 2015 | Head and neck cancers | MA (5 r 2a.s., 1 nr 2a.s.) | RT | 32–80 à 1.8–2 Gy | 232 | – | CR: 39.6% |
| RTHT | 219 | 1–2x/w | CR: 62.5%, OR 2.92, p = 0.001, RR 1.61, p < 0.001 | |||||
| Kang et al. (88) | 2013 | Nasopharyngeal cancer (N2/3) | r pIII | RTCT | 50/78 à 2 Gy +cisplatin |
78 | – | CR: 62.8% |
| 5y-DFS: 20.5% | ||||||||
| 5y-OS: 50% | ||||||||
| RTCTHT | +cisplatin | 76 | 3 groups: 0.5–2x/w | CT: 81.6%, p < 0.05 | ||||
| 5y-DFS: 51.3%, p < 0.05 | ||||||||
| 5y-OS:68.4%, p < 0.05 | ||||||||
| Hua et al. (89) | 2011 | Nasopharyngeal cancer | r pIII | RT(CT) | 50/60/70 Gy ± BT: (15–20 Gy) ±(T3/4) cisplatin/5FU |
90 | – | CR: 81.1% |
| 5y-DFS: 63.1% | ||||||||
| 5y-OS: 70.3% | ||||||||
| RT(CT)HT | +(T3/4) cisplatin/5FU | 90 | 2x/w | CR: 95.6%, p = 0.003 | ||||
| 5y-DFS: 72.7%, p = 0.039 | ||||||||
| 5y-OS: 78.2%, p = 0.14 | ||||||||
| Zhao et al. (90) | 2014 | Nasopharyngeal cancer | r pIII | RTCT | 50/70–74 Gy +cisplatin/paclitaxel |
40 | – | 3y-OS: 53.5% |
| mPFS: 37.5 | ||||||||
| RTCTHT | +cisplatin/paclitaxel | 43 | 3x/w | Better quality of life | ||||
| 3y-OS: 73%, p = 0.041 | ||||||||
| mPFS: 48 mo, p = 0.05 | ||||||||
| Rectal cancer | ||||||||
| De Haas-Kock et al. (93) | 2009 | Locally advanced rectal cancer | MA (6 r 2a.s.) | RT | 40–50 Gy | 258 | – | |
| RTHT | 262 | 1–5x/w | 2y-OS: HR 2.06, p = 0.001 | |||||
| CR: RR: 2.81, p = 0.01 | ||||||||
RT, CT, and HT schemes, p-value are described as mentioned in the original publications.
a.s., arm study; BT, brachytherapy; CT, chemotherapy; CR, complete response; DFS, disease-free survival; HR, hazard ratio; HT, hyperthermia; m, mean; mo, months; nr, non-randomized; MA, meta–analysis; OS, overall survival; OR, odds ratio; P #, patient number; p, phase; w, week; PFS, progression-free survival; r, randomized; RR, relative risk; RT, radiotherapy; y, years; RTHT, thermoradiotherapy; RTCT, chemoradiotherapy; à, with a single dose of; x/w, times per week.